Skip to main content

Clinical evaluation of biologically targeted drugs: Obstacles and opportunities

Cancer Chemotherapy and Pharmacology volume 42, pages S3–S21 (1998)Cite this article

Abstract

Recent insights into the molecular mechanisms of cancer have indicated that a variety of fundamental cellular processes are dysregulated in malignant cells. These processes include cell cycle control, signal transduction pathways, apoptosis, telomere stability, angiogenesis, and interactions with the extracellular matrix. Remarkable advances in molecular genetics, enzymology, and medicinal chemistry have permitted the design of compounds that modulate some of these processes with specificity that was unimaginable a decade ago. As these novel, biologically targeted compounds enter the clinic, they will require a strategy for clinical evaluation and development different from that used commonly for cytotoxic antineoplastic agents. This review examines the development of cancer drugs directed against angiogenesis, metastasis, signal transduction, telomerase, and molecular message (anti-sense), outlines strategies for the clinical testing of agents directed at these processes, and contrasts these efforts with traditional approaches to cancer drug testing.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Abramovitch R, Meir G, Neeman M (1995) Neovascularization induced growth of implanted C6 glioma multicellular spheroids: magnetic resonance microimaging. Cancer Res 55:1956

    PubMed  CAS  Google Scholar 

  2. An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJ, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, Moossa AR, Hoffman RM (1997) Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis 15:184

    PubMed  CAS  Google Scholar 

  3. Anderson IC, Shipp MA, Docherty AJ, Teicher BA (1996) Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 56:715

    CAS  Google Scholar 

  4. Baish JW, Netti PA, Jain RK (1997) Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res 53:128

    PubMed  CAS  Google Scholar 

  5. Barbareschi M, Gasparini G, Morelli L, Forti S, Dalla Palma P (1995) Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res Treat 36:181

    PubMed  CAS  Google Scholar 

  6. Barinaga M (1997) Cancer research: from bench top to bedside. Science 278:1036

    PubMed  CAS  Google Scholar 

  7. Bayever E, Haines KM, Iversen PL, Ruddon RW, Pirruccello SJ, Mountjoy CP, Arneson MA, Smith LJ (1994) Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribo-nucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk Lymphoma 12:223

    PubMed  CAS  Google Scholar 

  8. Bertram J, Palfner K, Killian M, Brysch W, Schlingensiepen KH, Hiddemann W, Kneba M (1995) Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anticancer Drugs 6:124

    PubMed  CAS  Google Scholar 

  9. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A (1996) Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14:1320

    PubMed  CAS  Google Scholar 

  10. Blackburn EH (1991) Structure and function of telomeres. Nature 350: 569

    PubMed  CAS  Google Scholar 

  11. Bodurtha A, Eisenhauer E, Steward W, Rusthoven J, Quirt I, Lehmann R, Wainman N, Rugg T (1997) Phase III study of marimastat (BB2516) in patients (pts) with metastatic melanoma. Proc Am Soc Clin Oncol 16:Abstract 1775

  12. Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404

    PubMed  CAS  Google Scholar 

  13. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327:293

    PubMed  CAS  Google Scholar 

  14. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755

    PubMed  CAS  Google Scholar 

  15. Boucher Y, Leunig M, Jain RK (1996) Tumor angiogenesis and interstitial hypertension. Cancer Res 56:4264

    PubMed  CAS  Google Scholar 

  16. Breier G, Damert A, Plate KH, Risau W (1997) Angiogenesis in embryos and ischemic diseases. Thromb Haemost 78:678

    PubMed  CAS  Google Scholar 

  17. Brem SS, Jensen HM, Gullino PM, Brem SS, Jensen HM, Gullino PM (1978) Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 41:239

    PubMed  CAS  Google Scholar 

  18. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157

    PubMed  CAS  Google Scholar 

  19. Chambers AF, Matrisian ML (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260

    PubMed  CAS  Google Scholar 

  20. Chen G, Oh S, Monia BP, Stacey DW (1996) Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 271:28259

    PubMed  CAS  Google Scholar 

  21. Cho-Chung YS (1996) Protein kinase A-directed antisense restrains cancer growth: sequence-specific inhibition of gene expression. Antisense Nucleic Acid Drug Dev 6:237

    PubMed  CAS  Google Scholar 

  22. Coleman RE, Sostman HD (1997) Technology for functional and metabolic imaging. In: DeVita JVT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, p 673

    Google Scholar 

  23. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70:73

    PubMed  CAS  Google Scholar 

  24. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11:1921

    PubMed  CAS  Google Scholar 

  25. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S (1995) Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85:2315

    PubMed  CAS  Google Scholar 

  26. Crooke ST (1992) Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329

    PubMed  CAS  Google Scholar 

  27. D’Amato R, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082

    PubMed  Google Scholar 

  28. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824

    PubMed  CAS  Google Scholar 

  29. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161

    PubMed  CAS  Google Scholar 

  30. de The H, Chomienne C, Lanotte M, Degos L, Dejean A (1990) The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347:558

    PubMed  Google Scholar 

  31. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M, Fabbro D (1996) Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res 56:3499

    PubMed  CAS  Google Scholar 

  32. Dean NM, McKay R (1994) Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 91:11762

    PubMed  CAS  Google Scholar 

  33. Del Bufalo D, Cucco C, Leonetti C, Citro G, I DA, Benassi M, Geiser T, Zon G, Calabretta B, Zupi G (1996) Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br J Cancer 74:387

    PubMed  Google Scholar 

  34. Dhanasekaran N, Heasley LE, Johnson GL (1995) G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev 16:259

    PubMed  CAS  Google Scholar 

  35. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP (1994) Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54:3253

    PubMed  CAS  Google Scholar 

  36. Dong Z, Kumar R, Yang X, Fidler IJ (1997) Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88:801

    PubMed  CAS  Google Scholar 

  37. Eisenhauer KM, Gerstein RM, Chin CP, Conti M, Hsueh AJ (1997) Telomerase activity in female and male rat germ cells undergoing meiosis and in early embryos. Biol Reprod 56:1120

    PubMed  CAS  Google Scholar 

  38. Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326:1456

    PubMed  CAS  Google Scholar 

  39. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL (1985) Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24:5480

    PubMed  CAS  Google Scholar 

  40. Figg WD, Bergan R, Brawley O, Tompkins A, Linehan M, Duray P, Bauer KS, Pluda J, Reed E (1997) Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 16:Abstract 1189

    Google Scholar 

  41. Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, Yarchoan R (1997) The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 17:91

    PubMed  CAS  Google Scholar 

  42. Fine HA, Loeffler JS, Kyritsis A, Wen P, Black PM, Levin VA, Graham S, Yung WKA (1997) A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent highgrade gliomas. Proc Am Soc Clin Oncol 16:Abstract 1372

    Google Scholar 

  43. Fletcher TM, Salazar M, Chen SF (1996) Human telomerase inhibition by 7-deaza-2’deoxypurine nucleoside triphosphates. Biochemistry 35:15611

    PubMed  CAS  Google Scholar 

  44. Folkman J (1997) Angiogenic therapy. In: DeVita JVT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, p 3075

    Google Scholar 

  45. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA (1996) Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 93:9764

    PubMed  CAS  Google Scholar 

  46. Reference deleted

  47. Gibbs JB (1991) Ras C-terminal processing enzymes—new drug targets? Cell 65:1

    PubMed  CAS  Google Scholar 

  48. Gibbs JB, Kohl NE, Koblan KS, Omer CA, Sepp-Lorenzino L, Rosen N, Anthony NJ, Conner MW, deSolms SJ, Williams TM, Graham SL, Hartman GD, Oliff A (1996) Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res Treat 38:75

    PubMed  CAS  Google Scholar 

  49. Gibbs JB, Oliff A, Kohl NE (1994) Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175

    PubMed  CAS  Google Scholar 

  50. Gimbrone MA Jr, Gullino PM (1976) Neovascularization induced by intraocular xenografts of normal, preneoplastic, and neoplastic mouse mammary tissues. J Natl Cancer Inst 56:305

    PubMed  Google Scholar 

  51. Goldfarb M, Shimizu K, Perucho M, Wigler M (1982) Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 296:404

    PubMed  CAS  Google Scholar 

  52. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87:6624

    PubMed  CAS  Google Scholar 

  53. Gradishar WJ, O’Regan RM, Liu J, Cisneros A, Rademaker A, Soft G, Benson AB, Bouck N (1997) Phase II trial of suramin (SUR) in metastatic (Met) breast cancer with an assessment of angiogenesis inhibition. Proc Am Soc Clin Oncol 16:Abstract 600

    Google Scholar 

  54. Greider CW, Blackburn EH (1987) The telomere terminal transferase of tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51:887

    PubMed  CAS  Google Scholar 

  55. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353

    PubMed  CAS  Google Scholar 

  56. Hancock JF, Magee AI, Childs JE, Marshall CJ (1989) All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167

    PubMed  CAS  Google Scholar 

  57. Harle-Bachor C, Boukamp P (1996) Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA 93:6476

    PubMed  CAS  Google Scholar 

  58. Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345:458

    PubMed  CAS  Google Scholar 

  59. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, Bacchetti S, Hirte HW, Counter CM, Greider CW, Piatyszek MA Wright WE, Shay IW (1994) Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol 59:307

    PubMed  CAS  Google Scholar 

  60. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I, Robinson MO (1997) A mammalian telomerase-associated protein. Science 275:973

    PubMed  CAS  Google Scholar 

  61. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC (1990) Telomere reduction in human colorectal carcinoma and with ageing. Nature 346:866

    PubMed  CAS  Google Scholar 

  62. Henry SP, Monteith D, Bennett F, Levin AA (1997) Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anti-cancer Drug Des 12:409

    CAS  Google Scholar 

  63. Hermine O, Haioun C, Lepage E, d ’Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 87:265

    PubMed  CAS  Google Scholar 

  64. Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan Hudson G, Mason D, Selby P, Linch DC (1996) Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood 88:1046

    PubMed  CAS  Google Scholar 

  65. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334

    PubMed  CAS  Google Scholar 

  66. Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149

    PubMed  CAS  Google Scholar 

  67. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120

    PubMed  CAS  Google Scholar 

  68. Hsiao R, Sharma HW, Ramakrishnan S, Keith E, Narayanan R (1997) Telomerase activity in normal human endothelial cells. Anticancer Res 17:827

    PubMed  CAS  Google Scholar 

  69. Hu GF, Riordan JF, Vallee BL (1997) A putative angiogenin receptor in angiogenin responsive human endothelial cells. Proc Natl Acad Sci USA 94:2204

    PubMed  CAS  Google Scholar 

  70. Huang SC, Phelps ME, Hoffman EJ, Kuhl DE (1979) A theoretical study of quantitative flow measurements with constant infusion of short-lived isotopes. Phys Med Biol 24:1151

    PubMed  CAS  Google Scholar 

  71. Hunter T (1997) Oncoprotein networks. Cell 88:333

    PubMed  CAS  Google Scholar 

  72. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555

    PubMed  CAS  Google Scholar 

  73. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ (1990) Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 87:3042

    PubMed  CAS  Google Scholar 

  74. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC Jr (1993) Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260:1937

    PubMed  CAS  Google Scholar 

  75. James GL, Goldstein JL, Pathak RK, Anderson RG, Brown MS (1994) PxF, a prenylated protein of peroxisomes. J Biol Chem 269:14182

    PubMed  CAS  Google Scholar 

  76. Jiang SX, Sato Y, Kuwao S, Kameya T (1995) Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177:135.

    PubMed  CAS  Google Scholar 

  77. Kameyama M, Ishiwata K, Tsurumi Y, Itoh J, Sato K, Katakura R, Yoshimoto T, Hatazawa J, Ito M, Ido T (1995) Clinical application of 18F-FUdR in glioma patients - PET study of nucleic acid metabolism. J Neurooncol 23:53

    PubMed  CAS  Google Scholar 

  78. Kanazawa Y, Ohkawa K, Ueda K, Mita E, Takehara T, Sasaki Y, Kasahara A, Hayashi N (1996) Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 225:570

    PubMed  CAS  Google Scholar 

  79. Keith FJ, Bradbury DA, Zhu YM, Russell NH (1995) Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 9:131

    PubMed  CAS  Google Scholar 

  80. Khokha R (1994) Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the over-expression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 86:299

    PubMed  CAS  Google Scholar 

  81. Sim BK, O’Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA (1997) A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57:1329

    PubMed  CAS  Google Scholar 

  82. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011

    PubMed  CAS  Google Scholar 

  83. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB (1993) Selective inhibition of ras-dependent transformation by a farnesyl-transferase inhibitor. Science 260:1934

    PubMed  CAS  Google Scholar 

  84. Kong HL, Song WR, Hecht D, Yayon A, Kovesdi I, Crystal RG (1997) Inhibition of angiogenesis and tumor growth following adenovirus vector-mediated in vivo transfer of the human soluble FLT receptor gene. Proc Am Soc Clin Oncol 16:Abstract 1536

    Google Scholar 

  85. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Soderstrom KO, Bergman J, Haaparanta M, Ruotsalainen U, Solin O, Ioensuu h (1995) Increased glucose metabolism in untreated non-Hodgkin’s lymphoma:a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522

    PubMed  CAS  Google Scholar 

  86. Le Beau MM (1997) Molecular biology of cancer: cytogenetics. In: DeVita JVT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, p 103

    Google Scholar 

  87. Leonetti C, D’Agnano I, Lozupone F, Valentine A, Geiser T, Zon G, Calabretta B, Citro GC, Zupi G (1996) Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice. J Natl Cancer Inst 88:419

    PubMed  CAS  Google Scholar 

  88. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR (1997) Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276:561

    PubMed  CAS  Google Scholar 

  89. Liu C, Qureshi IA, Ding X, Shan Y, Huang Y, Xie Y, Ji M (1996) Modulation of multidrug resistance gene (mdr-1) with antisense oligodeoxynucleotides. Clin Sci 91:93

    PubMed  CAS  Google Scholar 

  90. Lush RM, Figg WD, Pluda JM, Bitton R, Headlee D, Kohler D, Reed E, Sartor O, Cooper MR (1996) A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Ann Oncol 7:939

    PubMed  CAS  Google Scholar 

  91. Maeda K, Chung YS, Takatsuka S, Ogawa Y Onoda N, Sawada T, Kato Y, Nitta A, Arimoto Y, Kondo Y, Sowa M (1995) Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 72:319

    PubMed  CAS  Google Scholar 

  92. Maione TE, Gray GS, Hunt AJ, Sharpe RJ (1991) Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 51:2077

    PubMed  CAS  Google Scholar 

  93. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55

    PubMed  CAS  Google Scholar 

  94. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W (1996) Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 106:1114

    PubMed  CAS  Google Scholar 

  95. Manzoli L, Billi AM, Rubbini S, Bavelloni A, Faenza I, Gilmour RS, Rhee SG, Cocco L (1997) Essential role for nuclear phos-pholipase C beta I in insulin-like growth factor I-induced mitogenesis. Cancer Res 57:2137

    PubMed  CAS  Google Scholar 

  96. Mata JE, Joshi SS, Palen B, Pirruccello SJ, Jackson JD, Elias N, Page TJ, Medlin KL, Iversen PL (1997) A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt’s lymphoma cells in vitro and in vivo. Toxicol Appl Pharmacol 144:189

    PubMed  CAS  Google Scholar 

  97. McGuire TF, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogt A, Hamilton AD, Sebti SM (1995) CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. Biochem Biophys Res Commun 214:295

    PubMed  CAS  Google Scholar 

  98. Melani C, Rivoltini L, Parmiani G, Calabretta B, Colombo MP (1991) Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res 51:2897

    PubMed  CAS  Google Scholar 

  99. Melnyk O, Shuman MA, Kim KJ (1996) Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56:921

    PubMed  CAS  Google Scholar 

  100. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddie SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA (1997) hEst2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785

    PubMed  CAS  Google Scholar 

  101. Mishima Y, Imahori Y, Honda C, Hiratsuka J, Ueda S, Ido T (1997) In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue. J Neurooncol 33:163

    PubMed  CAS  Google Scholar 

  102. Miyake M, Mizutani S, Koide H, Kaziro Y (1996) Unfarnesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable Ras.Raf complex in the cytosol. FEBS Lett 378:15

    PubMed  CAS  Google Scholar 

  103. Miyashita T, Reed JC (1992) bcl-2 gene transfer increases relative resistance of S49.1 and Wehi7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407

    PubMed  CAS  Google Scholar 

  104. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O (1994) Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 74:2546

    PubMed  CAS  Google Scholar 

  105. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxy-nucleotide targeted against C-raf kinase. Nat Med 2:668

    PubMed  CAS  Google Scholar 

  106. Monia BP, Johnston JF, Sasmor H, Cummins LL (1996) Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J Biol Chem 271:14533

    PubMed  CAS  Google Scholar 

  107. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM (1993) Evaluation of 2’-modified oligonucleotides containing 2’-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268:14514

    PubMed  CAS  Google Scholar 

  108. Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H, Fabbro D (1996) Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 93:15481

    PubMed  CAS  Google Scholar 

  109. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF, Crooke ST (1997) Immune stimulation — a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 12:421

    PubMed  CAS  Google Scholar 

  110. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955

    PubMed  CAS  Google Scholar 

  111. Nakayama J, Saito M, Nakamura H, Matsuura A, Ishikawa F (1997) TLP 1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell 88:875

    PubMed  CAS  Google Scholar 

  112. Nemunaitis J, Eckhardt G, Dorr A, Pribble J, Smith R, Bruce J, Ognoskie N, Von Hoff D (1997) Phase I evaluation of CGP 64128A, an antisense inhibitor of protein kinase C-α. (PKC α), in patients with refractory cancer. Proc Am Soc Clin Oncol 16:Abstract 870

    Google Scholar 

  113. Netti PA, Roberge S, Boucher Y Baxter LT, Jain RK (1996) Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 52:27

    PubMed  CAS  Google Scholar 

  114. Ngan BY, Chen-Levy Z, Weiss LM, Wamke RA, Cleary ML (1988) Expression in non-Hodgkin’s lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 318:1638

    PubMed  CAS  Google Scholar 

  115. Norrback KF, Dahlenborg K, Carlsson R, Roos G (1996) Telomerase activation in normal B lymphocytes and non-Hodgkin’s lymphomas. Blood 88:222

    PubMed  CAS  Google Scholar 

  116. O’Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277

    PubMed  Google Scholar 

  117. O’Reilly M, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689

    PubMed  Google Scholar 

  118. O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315

    PubMed  Google Scholar 

  119. Ohyashiki JH, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A, Toyama K (1994) Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 54:3557

    PubMed  CAS  Google Scholar 

  120. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K (1997) Postoperative radiotherapy in high-risk pre-menopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949

    CAS  Google Scholar 

  121. Passe TJ, Bluemke DA, Siegelman SS (1997) Tumor angiogenesis: tutorial on implications for imaging. Radiology 203:593

    PubMed  CAS  Google Scholar 

  122. Perkins AS, Stem DF (1997) Molecular biology of cancer: oncogenes. In: DeVita JVT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, p 79

    Google Scholar 

  123. Pezzella F, Jones M, Ralfkiaer E, Ersboll J, Gatter KC, Mason DY (1992) Evaluation of bcl2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 65:87

    PubMed  CAS  Google Scholar 

  124. Plenat F, Klein-Monhoven N, Marie B, Vignaud JM, Duprez A (1995) Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistological, and direct fluorescence microscopy study. Am J Pathol 147:124

    PubMed  CAS  Google Scholar 

  125. Prehn RT (1991) The inhibition of tumor growth by tumor mass. Cancer Res 51:2

    PubMed  CAS  Google Scholar 

  126. Pruim J, Willemsen AT, Molenaar WM, van Waarde A, Paans AM, Heesters MA, Go KG, Visser GM, Franssen EJ, Vaalburg W (1995) Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 197:221

    PubMed  CAS  Google Scholar 

  127. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, Wilson KS, Knowling MA, Coppin CM, Paradis M, Coldman AJ, Olivotto IA (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956

    PubMed  CAS  Google Scholar 

  128. Ramirez RD, Wright WE, Shay JW, Taylor RS (1997) Telomerase activity concentrates in the mitotically active segments of human hair follicles. J Invest Dermatol 108:113

    PubMed  CAS  Google Scholar 

  129. Rasmussen H, Rugg T, Brown P, Baillet M, Millar A (1997) A 371 patient meta-analysis of studies of marimastat in patients with advanced cancer. Proc Am Soc Clin Oncol 16:Abstract 1538

    Google Scholar 

  130. Rasouli-Nia A, Liu D, Perdue S, Britten RA (1998) High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin Cancer Res 4: 1111

    PubMed  CAS  Google Scholar 

  131. Rastinejad F, Polverini PJ, Bouck NP (1989) Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56:345

    PubMed  CAS  Google Scholar 

  132. Reed JC (1995) Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541

    PubMed  CAS  Google Scholar 

  133. Reed JC, Stein C, Subasinghe C, Haldar S, Croce CM, Yum S, Cohen J (1990) Antisense-mediated inhibition of BCL2 proto-oncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeox-ynucleotides. Cancer Res 50:6565

    PubMed  CAS  Google Scholar 

  134. Richardson GE, Johnson BE (1993) The biology of lung cancer. Semin Oncol 20:105

    Google Scholar 

  135. Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ (1993) Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neurooncol 15:57

    PubMed  CAS  Google Scholar 

  136. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thuong NT, Helene C (1991) Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J 10:1111

    PubMed  CAS  Google Scholar 

  137. Santos O, McDermott CD, Daniels RG, Appelt K (1997) Rodent pharmacokinetic and antitumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis 15:499

    PubMed  CAS  Google Scholar 

  138. Sarmiento UM, Perez JR, Becker JM, Narayanan R (1994) In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev 4:99

    PubMed  CAS  Google Scholar 

  139. Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF (1988) Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 48:5539

    PubMed  CAS  Google Scholar 

  140. Schwartsmann G, Sprinz E, Kalakun L, Yamagushi N, Sander E, Grivicich I, Koya R, Mans DR (1996) Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi’s sarcoma. Tumori 82:360

    PubMed  CAS  Google Scholar 

  141. Sebti SM, Hamilton AD (1996) Rational design of Ras prenyl-transferase inhibitors as potential anticancer drugs. Biochem Soc Trans 24:692

    PubMed  CAS  Google Scholar 

  142. Senger DR, Brown LF, Claffey KP, Dvorak HF (1994) Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis 14:385

    PubMed  CAS  Google Scholar 

  143. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N (1995) A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55:5302

    PubMed  CAS  Google Scholar 

  144. Sharina HW, Hsiao R, Narayanan R (1996) Telomerase as a potential molecular target to study G-quartet phosphorothioates. Antisense Nucleic Acid Drug Dev 6:3

    Google Scholar 

  145. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE (1990) Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82:848

    PubMed  CAS  Google Scholar 

  146. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787

    PubMed  CAS  Google Scholar 

  147. Siegel RM, Katsumata M, Miyashita T, Louie DC, Greene MI, Reed JC (1992) Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc Natl Acad Sci USA 89:7003

    PubMed  CAS  Google Scholar 

  148. Sikic BI, Yuen AR, Halsey J, Fisher GA, Pribble JP, Smith RM, Dorr A (1997) A phase I trial of an antisense oligonucleotide targeted to protein kinase C-α (ISIS 3521) delivered by 21-day continuous intravenous infusion. Proc Am Soc Clin Oncol 16:Abstract 741

    Google Scholar 

  149. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B (1994) Suppression of Philadelphia 1 leukemia cell growth in mice by BCR-ABL anti-sense oligodeoxynucleotide. Proc Natl Acad Sci USA 91:4504

    PubMed  CAS  Google Scholar 

  150. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Comelisse CJ, Bos JL (1988) KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 16:7773

    PubMed  CAS  Google Scholar 

  151. Smolin G, Hyndiuk RA (1971) Lymphatic drainage from vascu-larized rabbit cornea. Am J Ophthalmol 72:147

    PubMed  CAS  Google Scholar 

  152. Smyth AP, Rook SL, Detmar M, Robinson GS (1997) Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. J Invest Dermatol 108:523

    PubMed  CAS  Google Scholar 

  153. Stein CA, Cheng YC (1993) Antisense oligonucleotides as therapeutic agents — is the bullet really magical? Science 261: 1004

    PubMed  CAS  Google Scholar 

  154. Stover B, Laubenberger J, Niemeyer C, Stahl F, Brandis M, Langer M (1995) Haemangiomatosis in children: value of MRI during therapy. Pediatr Radiol 25:123

    PubMed  CAS  Google Scholar 

  155. Strahl C, Blackburn EH (1996) Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16:53

    PubMed  CAS  Google Scholar 

  156. Sun J, Qian Y, Hamilton AD, Sebti SM (1995) Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55:4243

    PubMed  CAS  Google Scholar 

  157. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguamera L, Venturelli D, Gewirtz AM, Calabretta B (1991) Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562

    PubMed  CAS  Google Scholar 

  158. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, Iki M (1996) Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 56:2671

    PubMed  CAS  Google Scholar 

  159. Tatematsu K, Nakayama J, Danbara M, Shionoya S, Sato H, Omine M, Ishikawa F (1996) A novel quantitative “stretch PCR assay”, that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias. Oncogene 13:2265

    PubMed  CAS  Google Scholar 

  160. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79:7837

    PubMed  CAS  Google Scholar 

  161. Teicher BA, Dupuis N, Kusumoto T, Robinson MF, Liu F, Menon K, Coleman CN (1995) Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 2:26

    Google Scholar 

  162. Teacher BA, Dupuis NP, Robinson MF, Emi Y, Goff DA (1995) Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 7:237

    Google Scholar 

  163. van Dijke CF, Brasch RC, Roberts TP, Weidner N, Mathur A, Shames DM, Mann JS, Demsar F, Lang P, Schwickert HC (1996) Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor micro-vasculature and histologie capillary density. Radiology 198:813

    PubMed  Google Scholar 

  164. van Steensel B, de Lange T (1997) Control of telomere length by the human telomeric protein TRF1. Nature 385:740

    PubMed  Google Scholar 

  165. Voest EE, Kenyon BM, MS OR, Truitt G, RJ DA, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581

    PubMed  CAS  Google Scholar 

  166. Wamil BD, Thurman GB, Sundell HW, DeVore RF, Wakefield G, Johnson DH, Wang YF, Hellerqvist CG (1997) Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. J Cancer Res Clin Oncol 123:173

    PubMed  CAS  Google Scholar 

  167. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD (1993) A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 54:363

    PubMed  CAS  Google Scholar 

  168. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726

    PubMed  CAS  Google Scholar 

  169. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137

    PubMed  CAS  Google Scholar 

  170. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875

    PubMed  CAS  Google Scholar 

  171. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med 324:1

    PubMed  CAS  Google Scholar 

  172. Weinstein JN, Myers TG, PM OC, Friend SH, Fomace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Pauli KD (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343

    PubMed  CAS  Google Scholar 

  173. Wellinger RJ, Sen D (1997) The DNA structures at the ends of eukaryotic chromosomes. Eur J Cancer 33:735

    PubMed  CAS  Google Scholar 

  174. Weng NP, Levine BL, June CH, Hodes RJ (1996) Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 183:2471

    PubMed  CAS  Google Scholar 

  175. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL (1989) Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 320:1197

    PubMed  CAS  Google Scholar 

  176. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR (1984) The p21 ras C-terminus is required for transformation and membrane association. Nature 310:583

    PubMed  CAS  Google Scholar 

  177. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ (1996) Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14:193

    PubMed  CAS  Google Scholar 

  178. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ (1997) Matrix metalloproteinase inhibitors. Invest New Drugs 15:61

    PubMed  CAS  Google Scholar 

  179. Woltering EA, Barrie R, TM OD, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J (1991) Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50:245

    PubMed  CAS  Google Scholar 

  180. Workman P, Brunton VG, Robins DJ (1994) Discovery and design of inhibitors of oncogenic tyrosine kinases. In: Workman P (ed) New approaches in cancer pharmacology: drug design and development, vol. 2. Springer-Verlag, New York, p 55

    Google Scholar 

  181. Yasumoto S, Kunimura C, Kikuchi K, Tahara H, Ohji H, Yamamoto H, Ide T, Utakoji T (1996) Telomerase activity in normal human epithelial cells. Oncogene 13:433

    PubMed  CAS  Google Scholar 

  182. Yegorov YE, Chernov DN, Akimov SS, Bolsheva NL, Krayevsky AA, Zelenin AV (1996) Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett 389:115

    PubMed  CAS  Google Scholar 

  183. Yoshimi N, Ino N, Suzui M, Hara A, Nakatani K, Sato S, Mori H (1996) Telomerase activity of normal tissues and neoplasms in rat colon carcinogenesis induced by methylazoxymethanol acetate and its difference from that of human colonic tissues. Mol Carcinog 16:1

    PubMed  CAS  Google Scholar 

  184. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765

    PubMed  CAS  Google Scholar 

  185. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U (1997) Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89:1027

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Massachusetts General Hospital Cancer Center, Boston, MA, USA

    Anthony L. Boral, Scott Dessain & Bruce A. Chabner

  2. Massachusetts General Hospital Cancer Center, Cox Building, 640, 100 Blossom Street, 02114, Boston, MA, USA

    Bruce A. Chabner

Authors
  1. Anthony L. Boral
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott Dessain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruce A. Chabner
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Work presented at the 13th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium, “Strategic Cross Talk between Major Oncology Groups/Clinical Pharmacology in Cancer Chemotherapy,” 17–18 October 1997, Nagoya, Japan

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Boral, A.L., Dessain, S. & Chabner, B.A. Clinical evaluation of biologically targeted drugs: Obstacles and opportunities. Cancer Chemother Pharmacol 42, S3–S21 (1998). https://doi.org/10.1007/s002800051075

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002800051075

Key words

  • Molecular mechanisms
  • Apoptosis
  • Telomerase
  • Angiogenesis
  • Antisense
  • Metastasis